aminocaproic acid has been researched along with Recrudescence in 40 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the safety and efficacy of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema." | 9.10 | A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. ( Bradford, CA; Faulkner, A; Fekrat, S; Goldberg, MF; Juzych, M; McLeod, SD; Melia, M; Parker, JS; Pieramici, DJ; Rosen, R; Santander, SH, 2003) |
| "The purpose of this study is to determine the incidence of secondary hemorrhage after traumatic hyphema in children and to evaluate the efficacy of epsilon aminocaproic acid in reducing this incidence." | 9.08 | Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. ( Barsoum-Homsy, M; Brunette, I; Chevrette, L; Jacob, JL; Milot, J; Orquin, J; Polomeno, RC; Quigley, MG; Teboul, BK, 1995) |
| "To determine whether topically applied aminocaproic acid, like systemic aminocaproic acid, effectively reduces secondary hemorrhage after hyphemas and to compare the safety and effectiveness of topical application with those of systemic use and a control group." | 9.08 | Topical aminocaproic acid in the treatment of traumatic hyphema. ( Chames, M; Crouch, ER; Gray, MK; Williams, PB, 1997) |
| "Forty-nine patients, ages 3 to 18 years, who sustained nonpenetrating unilateral trauma with hyphemas were assigned randomly to receive either 100 mg/kg of epsilon-aminocaproic acid (EACA), an antifibrinolytic agent, orally every 4 hours for 5 days (maximum 30 g/day) or a placebo." | 9.06 | Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. ( Antoszyk, JH; Christianson, MD; Crawford, JS; Kraft, SP; Wagman, RD, 1987) |
| "Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar)." | 9.06 | A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. ( Anderson, RJ; Fiscella, R; Frenkel, M; Goldberg, MF; Palmer, DJ, 1986) |
| "We performed a prospective study involving 96 patients undergoing vitrectomy for proliferative diabetic retinopathy to determine the effect of epsilon-aminocaproic acid on the occurrence of postoperative intraocular hemorrhage." | 9.05 | Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. ( Auer, C; de Bustros, S; Glaser, BM; Michels, RG, 1985) |
| "5 g of epsilon-aminocaproic acid (EACA) per hour after subarachnoid hemorrhage (SAH) from an intracranial aneurysm." | 7.67 | Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. ( Bakay, RA; Burchiel, KJ; Hoffman, JM, 1984) |
| "Systemically administered aminocaproic acid has been shown to reduce the incidence of secondary hemorrhage after traumatic hyphema." | 7.67 | Topical aminocaproic acid significantly reduces the incidence of secondary hemorrhage in traumatic hyphema in the rabbit model. ( Allingham, RR; Catlin, JC; Crouch, ER; Jacobson, J; Loewy, DM; Williams, PB, 1988) |
| "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH)." | 7.66 | Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. ( Benjamin, SP; Dohn, DE; Tubbs, RR, 1979) |
| "To determine the safety and efficacy of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema." | 5.10 | A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. ( Bradford, CA; Faulkner, A; Fekrat, S; Goldberg, MF; Juzych, M; McLeod, SD; Melia, M; Parker, JS; Pieramici, DJ; Rosen, R; Santander, SH, 2003) |
| "The purpose of this study is to determine the incidence of secondary hemorrhage after traumatic hyphema in children and to evaluate the efficacy of epsilon aminocaproic acid in reducing this incidence." | 5.08 | Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children. ( Barsoum-Homsy, M; Brunette, I; Chevrette, L; Jacob, JL; Milot, J; Orquin, J; Polomeno, RC; Quigley, MG; Teboul, BK, 1995) |
| "To determine whether topically applied aminocaproic acid, like systemic aminocaproic acid, effectively reduces secondary hemorrhage after hyphemas and to compare the safety and effectiveness of topical application with those of systemic use and a control group." | 5.08 | Topical aminocaproic acid in the treatment of traumatic hyphema. ( Chames, M; Crouch, ER; Gray, MK; Williams, PB, 1997) |
| "Forty-nine patients, ages 3 to 18 years, who sustained nonpenetrating unilateral trauma with hyphemas were assigned randomly to receive either 100 mg/kg of epsilon-aminocaproic acid (EACA), an antifibrinolytic agent, orally every 4 hours for 5 days (maximum 30 g/day) or a placebo." | 5.06 | Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid. ( Antoszyk, JH; Christianson, MD; Crawford, JS; Kraft, SP; Wagman, RD, 1987) |
| "Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar)." | 5.06 | A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. ( Anderson, RJ; Fiscella, R; Frenkel, M; Goldberg, MF; Palmer, DJ, 1986) |
| "We performed a prospective study involving 96 patients undergoing vitrectomy for proliferative diabetic retinopathy to determine the effect of epsilon-aminocaproic acid on the occurrence of postoperative intraocular hemorrhage." | 5.05 | Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. ( Auer, C; de Bustros, S; Glaser, BM; Michels, RG, 1985) |
| " Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))." | 3.81 | Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015) |
| "Long-term administration of the antifibrinolytic agent epsilon aminocaproic acid (EACA) reduces the rate of rehemorrhage in patients with aneurysmal subarachnoid hemorrhage (SAH), but is associated with cerebral ischemia." | 3.76 | Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus. ( Ardelt, AA; Fisher, WS; Harrigan, MR; Rajneesh, KF, 2010) |
| "5 g of epsilon-aminocaproic acid (EACA) per hour after subarachnoid hemorrhage (SAH) from an intracranial aneurysm." | 3.67 | Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. ( Bakay, RA; Burchiel, KJ; Hoffman, JM, 1984) |
| "The incidence and severity of cerebral vasospasm and hydrocephalus following induced subarachnoid hemorrhage in an experimental group of animals that subsequently received epsilon-aminocaproic acid was compared to that seen in a control group that received no antifibrinolytic therapy." | 3.67 | An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus. ( Dujovny, M; Heros, RC; Kenning, JA; Latchaw, RE; Nelson, D, 1984) |
| "Systemically administered aminocaproic acid has been shown to reduce the incidence of secondary hemorrhage after traumatic hyphema." | 3.67 | Topical aminocaproic acid significantly reduces the incidence of secondary hemorrhage in traumatic hyphema in the rabbit model. ( Allingham, RR; Catlin, JC; Crouch, ER; Jacobson, J; Loewy, DM; Williams, PB, 1988) |
| " The contusion caused a recurrent hyphema which lasted approximately 6 weeks and responded to epsilon-aminocaproic acid treatment." | 3.66 | Recurrent traumatic hyphema due to increased local fibrinolysis. ( Barishak, R; Kaufman, S; Zehavi, H, 1980) |
| "One hundred consecutive patients treated with epsilon aminocaproic acid 24 grams daily prior to surgery for ruptured intracranial aneurysms have been compared with the previous 100 patients managed similarly but without anti-fibrinolytic drugs." | 3.66 | Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. ( Ameen, AA; Illingworth, R, 1981) |
| "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH)." | 3.66 | Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. ( Benjamin, SP; Dohn, DE; Tubbs, RR, 1979) |
| "The incidence of hydrocephalus or symptomatic vasospasm was not unduly elevated in patients receiving preoperative EACA." | 1.30 | Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. ( Horner, TG; Leipzig, TJ; Redelman, K, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (60.00) | 18.7374 |
| 1990's | 11 (27.50) | 18.2507 |
| 2000's | 2 (5.00) | 29.6817 |
| 2010's | 3 (7.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ford, PA | 1 |
| Grant, SJ | 1 |
| Mick, R | 1 |
| Keck, G | 1 |
| Foreman, PM | 1 |
| Chua, M | 1 |
| Harrigan, MR | 2 |
| Fisher, WS | 2 |
| Tubbs, RS | 1 |
| Shoja, MM | 1 |
| Griessenauer, CJ | 1 |
| Rajneesh, KF | 1 |
| Ardelt, AA | 1 |
| Pieramici, DJ | 1 |
| Goldberg, MF | 3 |
| Melia, M | 1 |
| Fekrat, S | 1 |
| Bradford, CA | 1 |
| Faulkner, A | 1 |
| Juzych, M | 1 |
| Parker, JS | 1 |
| McLeod, SD | 1 |
| Rosen, R | 1 |
| Santander, SH | 1 |
| Wilker, SC | 1 |
| Singh, A | 1 |
| Ellis, FJ | 1 |
| Burchak, EN | 1 |
| Burchiel, KJ | 1 |
| Hoffman, JM | 1 |
| Bakay, RA | 1 |
| Kenning, JA | 1 |
| Heros, RC | 1 |
| Dujovny, M | 1 |
| Latchaw, RE | 1 |
| Nelson, D | 1 |
| Smith, RR | 1 |
| Chowdhary, UM | 2 |
| Sayed, K | 1 |
| Zehavi, H | 1 |
| Kaufman, S | 1 |
| Barishak, R | 1 |
| Ameen, AA | 1 |
| Illingworth, R | 1 |
| Glick, R | 1 |
| Green, D | 1 |
| Ts'ao, C | 1 |
| Witt, WA | 1 |
| Yu, AT | 1 |
| Raimondi, AJ | 1 |
| Alvarez Garijo, JA | 1 |
| Vilches, JJ | 1 |
| Aznar, JA | 1 |
| Shucart, WA | 1 |
| Hussain, SK | 1 |
| Cooper, PR | 1 |
| Skriabin, ON | 2 |
| Karitskiĭ, AP | 1 |
| Winter, SS | 1 |
| Chaffee, S | 1 |
| Kahler, SG | 1 |
| Graham, ML | 1 |
| Kurygin, AA | 1 |
| Grinev, MV | 1 |
| Baranchuk, VN | 1 |
| Serova, LS | 1 |
| Korobchenko, AA | 1 |
| Leipzig, TJ | 1 |
| Redelman, K | 1 |
| Horner, TG | 1 |
| Teboul, BK | 1 |
| Jacob, JL | 1 |
| Barsoum-Homsy, M | 1 |
| Brunette, I | 1 |
| Chevrette, L | 1 |
| Milot, J | 1 |
| Orquin, J | 1 |
| Polomeno, RC | 1 |
| Quigley, MG | 1 |
| Grover, N | 1 |
| Johnson, A | 1 |
| Schisano, G | 1 |
| Nina, P | 1 |
| Crouch, ER | 3 |
| Williams, PB | 2 |
| Gray, MK | 1 |
| Chames, M | 1 |
| Shiuey, Y | 1 |
| Lucarelli, MJ | 1 |
| Carey, PC | 1 |
| Hussein, MM | 1 |
| Tubbs, RR | 1 |
| Benjamin, SP | 1 |
| Dohn, DE | 1 |
| Peerless, SJ | 1 |
| Varas Lorenzo, MJ | 1 |
| López Martínez, A | 1 |
| Gordillo Bernal, J | 1 |
| Mundet Surroca, J | 1 |
| Mikunis, RI | 1 |
| Salobaĭ, VA | 1 |
| Lozitsky, VP | 1 |
| Puzis, LE | 1 |
| Biller, J | 1 |
| Godersky, JC | 1 |
| Adams, HP | 1 |
| Allingham, RR | 1 |
| Catlin, JC | 1 |
| Loewy, DM | 1 |
| Jacobson, J | 1 |
| Kraft, SP | 1 |
| Christianson, MD | 1 |
| Crawford, JS | 1 |
| Wagman, RD | 1 |
| Antoszyk, JH | 1 |
| Rehák, S | 1 |
| Nedelec, G | 1 |
| Didelot, F | 1 |
| Giudicelli, CP | 1 |
| Perrot, S | 1 |
| Debord, T | 1 |
| Brouard, R | 1 |
| Rougier, Y | 1 |
| Chernin, VV | 1 |
| Chibineev, SM | 1 |
| de Bustros, S | 1 |
| Glaser, BM | 1 |
| Michels, RG | 1 |
| Auer, C | 1 |
| Palmer, DJ | 1 |
| Frenkel, M | 1 |
| Fiscella, R | 1 |
| Anderson, RJ | 1 |
| Ruelle, A | 1 |
| Lasio, G | 1 |
| Boccardo, M | 1 |
| Gottlieb, A | 1 |
| Severi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study[NCT01996436] | Phase 4 | 330 participants (Anticipated) | Interventional | 2016-08-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 trials available for aminocaproic acid and Recrudescence
| Article | Year |
|---|---|
A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aminocaproic Acid; Anterior Chamber; Antifibrinoly | 2003 |
EACA and subarachnoid hemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Humans; Recurrence; Subarachnoid Hemorr | 1981 |
Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxyli | 1981 |
Clinical evaluation of aminocaproic acid for managing traumatic hyphema in children.
Topics: Administration, Oral; Aminocaproic Acid; Antifibrinolytic Agents; Child; Double-Blind Method; Eye In | 1995 |
Topical aminocaproic acid in the treatment of traumatic hyphema.
Topics: Administration, Topical; Adult; Aminocaproic Acid; Anterior Eye Segment; Antifibrinolytic Agents; Do | 1997 |
Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Arteriovenous Fistula; Basilar Artery; C | 1979 |
[Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer].
Topics: Adult; Aluminum Hydroxide; Aminocaproates; Aminocaproic Acid; Antacids; Anti-Ulcer Agents; Female; G | 1991 |
Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Child; Child, Preschool; Clinical Trials as To | 1987 |
Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage.
Topics: Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Diabetic Retinopathy; Eye Diseases; Fol | 1985 |
A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas.
Topics: Administration, Topical; Adolescent; Adrenal Cortex Hormones; Adult; Aminocaproates; Aminocaproic Ac | 1986 |
30 other studies available for aminocaproic acid and Recrudescence
| Article | Year |
|---|---|
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C | 2015 |
Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis: A case-control study.
Topics: Adult; Aged; Aminocaproic Acid; Aneurysm, Ruptured; Angiography, Digital Subtraction; Antifibrinolyt | 2015 |
Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Brain Ischem | 2010 |
Recurrent bleeding following traumatic hyphema due to mild hemophilia B (Christmas disease).
Topics: Aminocaproic Acid; Anterior Eye Segment; Antifibrinolytic Agents; Child; Eye Injuries; Hemophilia B; | 2007 |
[Use of epsilon-aminocaproic acid in the combined treatment of chronic noncalculous cholecystitis].
Topics: Aminocaproates; Aminocaproic Acid; Cholecystitis; Chronic Disease; Drug Therapy, Combination; Female | 1982 |
Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Cerebral Arteries; Depression, Chemical; | 1984 |
An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Cerebral Angiography; Cerebral Hemorrhage; Hydrocephalus | 1984 |
Recurrent traumatic hyphema due to increased local fibrinolysis.
Topics: Adult; Aminocaproic Acid; Blood Coagulation Factors; Eye Injuries; Humans; Hyphema; Male; Recurrence | 1980 |
Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm.
Topics: Adolescent; Adult; Aged; Aminocaproates; Aminocaproic Acid; Antifibrinolytic Agents; Child; Female; | 1981 |
High does epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage.
Topics: Adult; Aged; Aminocaproates; Aminocaproic Acid; Bleeding Time; Blood Coagulation; Female; Humans; In | 1981 |
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
Topics: Aminocaproic Acid; Cyclohexanecarboxylic Acids; Fibrin Fibrinogen Degradation Products; Humans; Intr | 1980 |
Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.
Topics: Aminocaproates; Aminocaproic Acid; Drug Evaluation; Humans; Intracranial Aneurysm; Recurrence; Subar | 1980 |
[Use of a new hemostatic preparation kaprofer in therapeutic endoscopy].
Topics: Aminocaproic Acid; Endoscopy; Ferric Compounds; Hemorrhage; Hemostatics; Humans; Recurrence | 1995 |
epsilon-Aminocaproic acid-associated myopathy in a child.
Topics: Aminocaproic Acid; Bone Marrow Transplantation; Child; Female; Humans; Muscular Diseases; Precursor | 1995 |
[The use of the hemostatic preparation Kaprofer in emergency surgery].
Topics: Acute Disease; Aminocaproic Acid; Drug Evaluation; Emergencies; Endoscopy, Digestive System; Ferric | 1995 |
Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Aneurysm, Ruptured; Antifibrinolytic Agents; Huma | 1997 |
Aminocaproic acid used to control upper gastrointestinal bleeding in radiation gastritis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Esophageal Neoplasms; Gastritis; Gastrointestinal | 1997 |
Antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Humans; Recurrence; Subarachnoid Hemorrhage; Tranexamic | 1997 |
The treatment of traumatic hyphema with topical epsilon-aminocaproic acid.
Topics: Administration, Topical; Aminocaproic Acid; Anterior Eye Segment; Antifibrinolytic Agents; Eye Injur | 1997 |
Traumatic hyphema and patient outcomes--an oversight.
Topics: Ambulatory Care; Aminocaproic Acid; Anterior Eye Segment; Eye Injuries; Humans; Hyphema; Recurrence; | 1998 |
Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.
Topics: Acute Disease; Aged; Aminocaproates; Aminocaproic Acid; Female; Humans; Recurrence; Renal Artery; Su | 1979 |
Pre- and postoperative management of cerebral aneurysms.
Topics: Aminocaproic Acid; Brain Edema; Humans; Hydrocephalus; Hypertension; Intracranial Aneurysm; Ischemic | 1979 |
[Dynamics of the kallikrein-kinin system in patients with recurrent rheumatic carditis associated with heart defects after administration of inhibitors of the kallikrein-kinin system in complex antirheumatic therapy].
Topics: Adult; Aminocaproic Acid; Aprotinin; Female; Heart Valve Diseases; Humans; Kallikreins; Kinins; Male | 1986 |
Resistance of mice to reinfection after E-aminocaproic acid treatment of primary influenza virus infection.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Female; Immunologic Memory; Influenza A virus; Lung; Mal | 1988 |
Management of aneurysmal subarachnoid hemorrhage.
Topics: Aminocaproic Acid; Humans; Intracranial Aneurysm; Nervous System Diseases; Nicardipine; Nimodipine; | 1988 |
Topical aminocaproic acid significantly reduces the incidence of secondary hemorrhage in traumatic hyphema in the rabbit model.
Topics: Acrylic Resins; Administration, Topical; Aminocaproates; Aminocaproic Acid; Animals; Corneal Injurie | 1988 |
[Preoperative care and treatment of acute subarachnoid hemorrhage].
Topics: Adolescent; Adult; Aged; Aminocaproic Acid; Fibrinolysis; Humans; Middle Aged; Preoperative Care; Re | 1987 |
[Recurrent macroscopic hematuria and heterozygote drepanocytosis].
Topics: Adult; Aminocaproic Acid; Anemia, Sickle Cell; Female; Hematuria; Heterozygote; Humans; Recurrence | 1987 |
[Use of epsilon-aminocaproic acid in recurrent peptic ulcer].
Topics: Administration, Oral; Adult; Aminocaproates; Aminocaproic Acid; Female; Follow-Up Studies; Humans; I | 1986 |
Long-term prognosis of subarachnoid hemorrhages of unknown etiology.
Topics: Adult; Aged; Aminocaproic Acid; Cerebral Angiography; Female; Follow-Up Studies; Humans; Hypertensio | 1985 |